A Phase 2a trial is recruiting people with idiopathic pulmonary fibrosis (IPF) to assess the effectiveness of GRI-0621, GRI Bio‘s investigational natural killer T-cell (NKT)-targeted therapy. The multicenter biomarker study, which was cleared to start by the U.S. Food and Drug Administration, is expected to have early results…
Trevi Therapeutics has launched a Phase 2b clinical trial testing therapeutic candidate Haduvio (nalbuphine extended-release tablets) for the treatment of chronic cough in people with idiopathic pulmonary fibrosis (IPF). The Phase 2b trial, CORAL (NCT05964335), plans to enroll about 160 adults with IPF and chronic cough. No…
The U.S. Food and Drug Administration (FDA) has given GRI Bio the green light to conduct a Phase 2 trial of its investigational natural killer T-cell (NKT)-targeted therapy, GRI-0621, in people with idiopathic pulmonary fibrosis (IPF). With the clearance of its investigational new drug (IND) application, the company…
Certain immune cells called natural killer (NK) T-cells are present at higher numbers in the lungs of people with idiopathic pulmonary fibrosis (IPF) than in the lungs of healthy people, according to data announced by GRI Bio. Also, the more NK T-cells, the greater the number of macrophages,…
The first patient has been enrolled in a Phase 3 clinical trial of nebulized Tyvaso (treprostinil) inhalation solution for treating progressive pulmonary fibrosis (PPF), according to United Therapeutics, the therapy’s developer. Called TETON PPF (NCT05943535), the study will evaluate how safe Tyvaso is versus a placebo…
The pharmaceutical company Humanetics will use a federal grant to fund a series of studies aimed at advancing the development of BIO 300 for idiopathic pulmonary fibrosis (IPF) — for one, testing the treatment candidate for its effectiveness in easing lung scarring, or fibrosis. BIO 300 is thought to…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF). Breakthrough therapy designation is intended to expedite the development and review of medicines for serious or life-threatening diseases. The decision is based on preliminary…
Use of cancer chemotherapy agents or rituximab to treat autoimmune diseases was associated with an increased risk of pulmonary fibrosis (PF) in people hospitalized with COVID-19, according to a large-scale U.S. study. Exposure to these medications, along with anti-inflammatory corticosteroids and amiodarone, used to treat certain heart rhythm disorders,…
LYT-100, PureTech Health’s oral treatment candidate for idiopathic pulmonary fibrosis (IPF), was well tolerated among healthy older adults at doses leading to much higher amounts of active medication in the body than the approved dose of Esbriet (pirfenidone). That’s according to new data from Phase 1 clinical…
Proteins called histones can trigger lung fibrosis (scarring) by prompting platelets, cell fragments involved in blood clotting, to release a signaling molecule called transforming growth factor beta 1 (TGFB1), a new study found. TGFB1, in turn, blocks the production of interleukin-27 (IL-27), a signaling molecule that normally helps to limit…
Get regular updates to your inbox.
